Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Recombinant human ADAMTS-13

EU orphan designation number: EU/3/08/588   
Active ingredient: Recombinant human ADAMTS-13
Indication: Treatment of thrombotic thrombocytopenic purpura
Sponsor: Baxalta Innovations GmbH
Industriestrasse 67, A-1221 Wien, Österreich

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/12/2008 Orphan designation EMEA/OD/056/08 (2008)8095 of 03/12/2008
15/04/2016 Transfer of orphan designation EMEA/OD/056/08/T/01 (2016)2261 of 13/04/2016